GENINUS Inc.

KOSDAQ:A389030 Stock Report

Market Cap: ₩96.7b

GENINUS Past Earnings Performance

Past criteria checks 0/6

GENINUS's earnings have been declining at an average annual rate of -18.7%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 39.8% per year.

Key information

-18.66%

Earnings growth rate

-17.98%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate39.80%
Return on equity-62.18%
Net Margin-166.33%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article Dec 18

Is GENINUS (KOSDAQ:389030) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Sep 03

Is GENINUS (KOSDAQ:389030) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article Dec 10

Is GENINUS (KOSDAQ:389030) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article Aug 07

Is GENINUS (KOSDAQ:389030) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article Apr 12

Is GENINUS (KOSDAQ:389030) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Revenue & Expenses Breakdown

How GENINUS makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A389030 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2610,241-17,0346,8923,211
31 Dec 2510,483-17,3737,0613,067
30 Sep 258,809-12,7979,5511,836
30 Jun 258,423-12,3448,8792,097
31 Mar 257,325-11,8358,2552,443
31 Dec 246,455-12,2738,8322,194
30 Sep 246,705-12,0688,6781,729
30 Jun 246,404-12,6539,7411,468
31 Mar 246,831-10,1397,9251,495
31 Dec 236,967-9,6847,0792,203
30 Sep 236,923-9,9225,6723,375
31 Dec 2210,083-9,3854,6595,327

Quality Earnings: A389030 is currently unprofitable.

Growing Profit Margin: A389030 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A389030 is unprofitable, and losses have increased over the past 5 years at a rate of 18.7% per year.

Accelerating Growth: Unable to compare A389030's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A389030 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).


Return on Equity

High ROE: A389030 has a negative Return on Equity (-62.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 14:03
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GENINUS Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.